Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Directorate Change

30 Sep 2021 07:00

RNS Number : 4462N
3i Group PLC
30 September 2021
 

3i Group plc

 

Chairman and Non-executive Director Appointments

 

 

Following the Company's announcement on 13 May 2021 that Simon Thompson would not seek re-election as Chairman of the Board at the Company's 2022 AGM, 3i Group plc is pleased to announce that David Hutchison, currently Senior Independent Director and Chairman of 3i's Valuations Committee, will become non-executive Chairman of the Board following the announcement of the Company's half-year results, which is expected to take place on 11 November 2021.

 

The selection process was conducted by a sub-committee of the Nominations Committee (which excluded Mr Thompson and Mr Hutchison) and included consideration of both internal and external candidates. The sub-committee was assisted by Russell Reynolds Associates.

 

3i Group plc is also pleased to announce the appointment of Lesley Knox as a non-executive Director of the Company with effect from 1 October 2021. 

 

Simon Thompson, 3i Chairman, said: "During my time as Chairman, the 3i team under Simon Borrows' leadership has significantly strengthened ESG management while achieving total shareholder returns of 19% per annum, despite the headwinds of COVID-19. David has been an outstanding Senior Independent Director and I wish him every success as he takes over as Chairman. I would also like to welcome Lesley Knox, who brings a wealth of international, strategic and financial services experience to the Board."

 

David Hutchison said: "It will be a great privilege to become Chairman of 3i and I look forward to helping continue the growth and success achieved during Simon Thompson's chairmanship." 

 

Lesley Knox said: "I am very pleased to be joining 3i's Board. 3i has a strong institutional franchise as well as a strong management team. Its conservative balance sheet strategy and the strength of its portfolio means it is well placed to continue to generate value for its shareholders."

 

Simon Borrows said "I am grateful to Simon for his leadership of the 3i Board, particularly through the COVID-19 pandemic. I look forward to working closely with David who has a deep knowledge of 3i, its portfolio and its culture. I am also pleased that Lesley Knox has been appointed to the Board. Together with the executive team, the Board is well placed to drive 3i's continued success."

 

For further information, contact:

Kathryn van der Kroft 020 7975 3021

Communications Director

 

Silvia Santoro 020 7975 3258

Investor Relations Director

 

Notes to Editors

 

About Lesley Knox

Lesley brings a wealth of international, strategic and financial services experience having spent over 18 years in senior roles in financial services, including with Kleinwort Benson and the Bank of Scotland. Lesley previously served as Chair of Alliance Trust PLC, as Senior Independent Director at Hays plc and non-executive director of SAB Miller plc, Centrica plc and Thomas Cook Group plc. Her current other appointments are: Legal & General Group plc (Non-executive director); Dovecot Studios Limited (Non-executive Director); Genus Plc (Senior Independent Non-Executive Director and Chair of Remuneration Committee); Grosvenor Group Limited pension fund (Trustee); National Galleries of Scotland Foundation (Trustee)

 

There is no further information required to be disclosed by Listing Rule 9.6.13 R.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOALLMFTMTJTBFB
Date   Source Headline
5th Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20264:24 pmRNSDirector/PDMR Shareholding
2nd Jun 20263:37 pmRNSDirector/PDMR Shareholding - Amendment
1st Jun 20264:28 pmRNSDirector/PDMR Shareholding
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:42 pmRNSTotal Voting Rights
29th May 20265:38 pmRNSAdmission to Trading
27th May 202610:42 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 202612:29 pmRNSDirector/PDMR Shareholding
21st May 20267:40 amRNSDoc re. 2026 Annual Report and Accounts
19th May 20262:28 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:24 amRNSDirector/PDMR Shareholding
14th May 202610:41 amRNSHolding(s) in Company
14th May 20267:02 amRNSCommencement of Share Buyback Programme
14th May 20267:00 amRNSResults for the year to 31 March 2026
1st May 202612:00 pmRNSDirector/PDMR Shareholding
30th Apr 20263:34 pmRNSTotal Voting Rights
30th Apr 20263:31 pmRNSAdmission to Trading
7th Apr 202612:33 pmRNSHolding(s) in Company
1st Apr 20269:53 amRNSPortfolio Update
1st Apr 20269:36 amRNSDirector/PDMR Shareholding
31st Mar 20262:30 pmRNSTotal Voting Rights
31st Mar 20262:29 pmRNSAdmission to Trading
31st Mar 202611:37 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:07 pmRNSAdmission to Trading
26th Mar 20267:00 amRNSAction Capital Markets Seminar & portfolio update
23rd Mar 202612:11 pmRNSHolding(s) in Company
2nd Mar 202612:18 pmRNSDirector/PDMR Shareholding
27th Feb 20264:00 pmRNSTotal Voting Rights
3rd Feb 202610:20 amRNSHolding(s) in Company
3rd Feb 202610:17 amRNSDirector Declaration
30th Jan 20262:24 pmRNSDirector/PDMR Shareholding
30th Jan 20261:47 pmRNSTotal Voting Rights
29th Jan 202612:19 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSFY2026 Q3 performance update
7th Jan 20262:06 pmRNSDirector/PDMR Shareholding
6th Jan 20261:53 pmRNSTotal Voting Rights
2nd Jan 202611:06 amRNSPortfolio Update
9th Dec 20251:11 pmRNSBlock listing Interim Review
4th Dec 20252:12 pmRNSDirector/PDMR Shareholding
1st Dec 20251:25 pmRNSDirector/PDMR Shareholding
28th Nov 20254:24 pmRNSTotal Voting Rights
20th Nov 20259:59 amRNSDirector/PDMR Shareholding
18th Nov 20252:23 pmRNSDirector/PDMR Shareholding
17th Nov 202512:50 pmRNSDirector/PDMR Shareholding
17th Nov 202512:48 pmRNSDirector/PDMR Shareholding
14th Nov 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.